We further assessed the occurrence of liver metastasis and found that combined anti-ERBB2 + anti-PD-1 nearly completely abrogated the formation of liver metastasis highlighting the impact of ERBB2 and anti-PD-1 blockade to prevent SCLC immune cell evasion (Fig. 9e). This evidence concerns the gene ERBB2 and small cell lung carcinoma.